Epitope and its use of hepatitis b virus surface antigen

Abstract

Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.

1 . A polynucleotide encoding a hepatitis B virus (HBV) specific epitope, said epitope comprising RFLWE (SEQ ID NO: 4) or KFLWE (SEQ ID NO: 5). 
     
     
         2 . The polynucleotide according to  claim 1 , wherein the HBV specific epitope comprises FARFLWEWASVRFSW (SEQ ID NO: 6) or FGKFLWEWASARFSW (SEQ ID NO: 7). 
     
     
         3 . A recombinant vector including the polynucleotide of  claim 1 . 
     
     
         4 . A recombinant vector including the polynucleotide of  claim 2 . 
     
     
         5 . The recombinant vector of  claim 3 , further comprising a sequence encoding a promoter or signal protein which derives expression of the HBV specific epitope on the surface of a microorganism cell or virus, or mammalian cells. 
     
     
         6 . The recombinant vector of  claim 4 , further comprising a sequence encoding a promoter or signal protein which allows an expression of the HBV specific epitope on the surface of a microorganism cell or virus, or mammalian cells. 
     
     
         7 . A host carrying the recombinant vector of  claim 3 , wherein said host is a recombinant microorganism, virus, or a mammalian cell transformed by the recombinant vector of  claim 3 . 
     
     
         8 . The host of  claim 7 , wherein the transformed recombinant microorganism, virus, or mammalian cell is selected from the group consisting of recombinant  E. coli , recombinant yeasts, recombinant bacteriophages, and recombinant mammalian cells. 
     
     
         9 . A host carrying the recombinant vector of  claim 4 , wherein said host is a recombinant microorganism, virus, or a mammalian cell transformed by the recombinant vector of  claim 4 . 
     
     
         10 . The host of  claim 9 , wherein the transformed recombinant microorganism, virus, or mammalian cell is selected from the group consisting of recombinant  E. coli , recombinant yeasts, recombinant bacteriophages, and recombinant mammalian cells. 
     
     
         11 . A host carrying the recombinant vector of  claim 5 , wherein said host is a recombinant microorganism, virus, or a mammalian cell transformed by the recombinant vector of  claim 5 . 
     
     
         12 . The host of  claim 11 , wherein the transformed recombinant microorganism, virus, or mammalian cell is selected from the group consisting of recombinant  E. coli , recombinant yeasts, recombinant bacteriophages, and recombinant mammalian cells. 
     
     
         13 . A host carrying the recombinant vector of  claim 6 , wherein said host is a recombinant microorganism, virus, or a mammalian cell transformed by the recombinant vector of  claim 6 . 
     
     
         14 . The host of  claim 13 , wherein the transformed recombinant microorganism, virus, or mammalian cell is selected from the group consisting of recombinant  E. coli , recombinant yeasts, recombinant bacteriophages, and recombinant mammalian cells. 
     
     
         15 . A method for preparing the hepatitis B virus (HBV) specific epitope, comprising:
 culturing a vector carrying a polynucleotide encoding the HBV specific epitope or a host carrying the vector in a culture medium to express the HBV specific epitope; and   recovering the HBV specific epitope from the culture,   wherein the HBV specific epitope has the sequence of SEQ ID NO: 4, 5, 6, or 7, and   wherein the host is a recombinant microorganism, virus, or mammalian cell transformed with the vector.   
     
     
         16 . The method of  claim 15 , wherein the vector further comprises a sequence encoding a promoter or signal protein which allows an expression of the HBV specific epitope on the surface of the host. 
     
     
         17 . The method of  claim 15 , wherein the host is selected from the group consisting of recombinant  E. coli , recombinant yeasts, recombinant bacteriophages, and recombinant mammalian cells.